http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9804265-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a717ea5b2ac78ac329ab3a9659d834d2 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-565 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-58 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-18 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-565 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P15-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-58 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-57 |
| filingDate | 1997-07-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_286f1e9f21b25457d84de3f18f539bc3 |
| publicationDate | 1998-02-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-9804265-A1 |
| titleOfInvention | Biphasic contraceptive method and kit comprising a combination of a progestin and estrogen |
| abstract | This invention provides a method of contraception which comprises administering to a female of child bearing age for 23-25 consecutive days, a first phase combination of a progestin at a daily dosage of 40-500 νg trimegestone, 250 νg - 4 mg dienogest, or 250 νg - 4 mg drospirenone, and an estrogen at a daily dosage equivalent in estrogenic activity to 10-20 νg ethinyl estradiol for 9-13 days beginning on day 1 of the menstrual cycle, wherein the same dosage of the progestin and estrogen combination is administered in each of the 9-13 days, and a second phase combination of a progestin at a daily dosage of 40-500 νg trimegestone, 250 νg - 4 mg dienogest, or 250 νg - 4 mg drospirenone, and an estrogen at a daily dosage equivalent in estrogenic activity to 10-20 νg ethinyl estradiol, for 11-15 days beginning on the day immediately following the last day of administration of the first phase combination, wherein the same dosage of the progestin and estrogen combination is administered in each of the 11-15 days, provided that the daily dosage of second phase progestin is greater than the daily dosage of the first phase progestin and that the daily dosage of the second phase estrogen is greater than or equal to the daily dosage of the first phase estrogen. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-RE37564-E http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-RE38253-E http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8349820-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-RE37838-E http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2003514861-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2008049172-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8071577-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7749987-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-RE43916-E http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-RE44159-E |
| priorityDate | 1996-07-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 143.